Skip to content


We continue to shape the future of the dialysis industry.

Outlook 2023 – updated on November 21, 2023

  Results basis 2022 Outlook 2023
Revenue1 EUR 19,398 million  Growth at low to mid-single digit percentage rate constant currency
Operating income1 EUR 1,540 million Growth by 12 to 14 percent at constant currency
(previously: Growth at a low-single digit percentage rate at constant currency) 


1 Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will be provided as separate KPI (“Revenue excluding special items”, “Operating income excluding special items”) to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items.
For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkey, the Humacyte investment remeasurement, and the net gain related to InterWell Health. Additionally, the basis (FY 2022) for the 2023 outlook was adjusted for Provider Relief Funding. For FY 2023, special items include costs related to the FME25 program, the Humacyte investment remeasurement, the costs associated with the legal form conversion and effects from legacy portfolio optimization.

Contact us for further information
Related content

Our annual and quarterly reports can be found in this section.

Find out more about our key operating figures and make use of the interactive analyst.